This case-control study aims to investigate the genetic and molecular bases of nicotine addiction to identify potential therapeutic targets. The project will involve drug repurposing using Mendelian Randomization, a smoking cessation intervention, and the analysis of methylation status in participants undergoing nicotine withdrawal.
Age range
18 Years – 60 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
Novel druggable gene targets for smoking cessation
Timeframe: Upon completion of Mendelian randomization analysis
Association between methylation of candidate genes and nicotine dependence scores
Timeframe: Baseline
Association between DNA methylation of candidate drug target genes and motivation to quit smoking scores
Timeframe: 3 and 6 months post nicotine cessation
Association between methylation and smoking relapse vulnerability
Timeframe: 3 and 6 months post nicotine cessation